126 related articles for article (PubMed ID: 8508880)
21. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.
J Clin Oncol; 1991 Sep; 9(9):1668-74. PubMed ID: 1831495
[TBL] [Abstract][Full Text] [Related]
22. Treatment of advanced and recurrent ovarian carcinoma with cyclophosphamide, doxorubicin, and cisplatin.
Belinson JL; McClure M; Ashikaga T; Krakoff IH
Cancer; 1984 Nov; 54(9):1983-90. PubMed ID: 6548172
[TBL] [Abstract][Full Text] [Related]
23. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study.
Lancet; 1998 Nov; 352(9140):1571-6. PubMed ID: 9843101
[TBL] [Abstract][Full Text] [Related]
24. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
[TBL] [Abstract][Full Text] [Related]
25. A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma.
Bertelsen K; Jakobsen A; Andersen JE; Ahrons S; Pedersen PH; Kiaer H; Arffmann E; Bichel P; Boestofte E; Strøyer I
Gynecol Oncol; 1987 Oct; 28(2):161-9. PubMed ID: 3311924
[TBL] [Abstract][Full Text] [Related]
26. Cisplatin and cyclophosphamide in early epithelial ovarian carcinoma.
Chiara S; Conte PF; Bruzzone M; Falcone A; Sertoli MR; Carnino F; Mossetti C; Iura R; Durando C; Guercio E
Chemioterapia; 1987 Oct; 6(5):380-3. PubMed ID: 3427698
[TBL] [Abstract][Full Text] [Related]
27. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma.
Hakes TB; Chalas E; Hoskins WJ; Jones WB; Markman M; Rubin SC; Chapman D; Almadrones L; Lewis JL
Gynecol Oncol; 1992 Jun; 45(3):284-9. PubMed ID: 1612505
[TBL] [Abstract][Full Text] [Related]
28. Comparative study of combination chemotherapy of ovarian cancer: cyclophosphamide, adriamycin and cisplatin versus 5-fluorouracil, cyclophosphamide and mitomycin C.
Sawada M; Yamasaki M; Urabe T; Ozaki M; Yanagita T; Takayama K; Taki I
Asia Oceania J Obstet Gynaecol; 1990 Dec; 16(4):315-21. PubMed ID: 2099727
[TBL] [Abstract][Full Text] [Related]
29. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
30. Cisplatin-containing versus cisplatin-free adjuvant chemotherapy in ovarian carcinoma. Results after second-look laparotomy.
Schneider J; Martin M; Erasun F; Matia JC; Rodriguez-Escudero FJ
Oncology; 1990; 47(2):109-11. PubMed ID: 2314822
[TBL] [Abstract][Full Text] [Related]
31. Treatment of fallopian tube carcinoma with cyclophosphamide, adriamycin, and cisplatin.
Cormio G; Maneo A; Gabriele A; Zanetta G; Losa G; Lissoni A
Am J Clin Oncol; 1997 Apr; 20(2):143-5. PubMed ID: 9124187
[TBL] [Abstract][Full Text] [Related]
32. Mature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma.
Cocconi G; Bella M; Lottici R; Leonardi F; Ceci G; Passalacqua R; Di Blasio B; Bordi C; Biscottini B; Melpignano M; De Biasi D; Finardi C; Bacchi M
Am J Clin Oncol; 1999 Dec; 22(6):559-67. PubMed ID: 10597739
[TBL] [Abstract][Full Text] [Related]
33. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer.
Kaye SB; Lewis CR; Paul J; Duncan ID; Gordon HK; Kitchener HC; Cruickshank DJ; Atkinson RJ; Soukop M; Rankin EM
Lancet; 1992 Aug; 340(8815):329-33. PubMed ID: 1353804
[TBL] [Abstract][Full Text] [Related]
34. Risks and benefits of cisplatin in ovarian cancer. A quality-adjusted survival analysis.
Willemse PH; van Lith J; Mulder NH; Aalders JG; Bouma J; de Vries EG; Sleijfer DT
Eur J Cancer; 1990 Mar; 26(3):345-52. PubMed ID: 2141492
[TBL] [Abstract][Full Text] [Related]
35. Long-term survival after chemotherapy with cisplatinum, adriamycin and cyclophosphamide for carcinoma of the ovary.
Davidson NG; Khanna S; Kirwan PH; Naftalin NJ; Roy UK; Chui D; Mitchell S
Clin Oncol (R Coll Radiol); 1990 Jul; 2(4):206-9. PubMed ID: 2261416
[TBL] [Abstract][Full Text] [Related]
36. Cisplatin-based combination chemotherapy with or without doxorubicin in advanced epithelial ovarian cancer: 8-year update of a randomized multicentric clinical trial. The Gruppo Oncologico Nord Ovest (GONO).
Gadducci A; Brunetti I; Bruzzone M; Carnino F; Chiara S; Conte PF; Fioretti P; Foglia G; Ragni N
Eur J Gynaecol Oncol; 1992; 13(1 Suppl):36-9. PubMed ID: 1511712
[TBL] [Abstract][Full Text] [Related]
37. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma.
Fanning J; Bennett TZ; Hilgers RD
Obstet Gynecol; 1992 Dec; 80(6):954-60. PubMed ID: 1333066
[TBL] [Abstract][Full Text] [Related]
38. [Increase in CDDP therapeutic index by lower concentration and longer infusion time--home chemotherapy for ovarian cancer].
Chen JT; Tatsuki Y; Hirai Y; Hasumi K
Gan To Kagaku Ryoho; 1993 Feb; 20(2):265-70. PubMed ID: 8434965
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy consisting of cisplatin, epirubicin, and cyclophosphamide in advanced ovarian carcinoma. The Gynecologic Oncology Group of the Comprehensive Cancer Center, Limburg, The Netherlands.
Stoot J; Wils J; von Geuns H; Smeets J; Schouten L
Cancer Invest; 1993; 11(1):1-5. PubMed ID: 8422593
[TBL] [Abstract][Full Text] [Related]
40. A five-drug alternating chemotherapy regimen for patients with advanced epithelial ovarian cancer.
Lawton F; Meanwell C; Mould J; Blackledge G
Gynecol Oncol; 1990 Jan; 36(1):19-22. PubMed ID: 2295447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
